618 related articles for article (PubMed ID: 7686889)
1. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
2. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
3. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
4. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
Renner C; Pfreundschuh M
J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
[TBL] [Abstract][Full Text] [Related]
5. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
Renner C; Ohnesorge S; Held G; Bauer S; Jung W; Pfitzenmeier JP; Pfreundschuh M
Blood; 1996 Jul; 88(1):236-41. PubMed ID: 8704179
[TBL] [Abstract][Full Text] [Related]
6. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
7. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
[TBL] [Abstract][Full Text] [Related]
8. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
[TBL] [Abstract][Full Text] [Related]
9. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
10. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
Renner C; Bauer S; Sahin U; Jung W; van Lier R; Jacobs G; Held G; Pfreundschuh M
Blood; 1996 Apr; 87(7):2930-7. PubMed ID: 8639913
[TBL] [Abstract][Full Text] [Related]
11. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
[TBL] [Abstract][Full Text] [Related]
12. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma.
Pohl C; Renner C; Schwonzen M; Schobert I; Liebenberg V; Jung W; Wolf J; Pfreundschuh M; Diehl V
Int J Cancer; 1993 May; 54(3):418-25. PubMed ID: 8389737
[TBL] [Abstract][Full Text] [Related]
13. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
14. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
15. Anti-idiotype vaccine against Hodgkin's lymphoma: induction of B- and T-cell immunity across species barriers against CD30 antigen by murine monoclonal internal image antibodies.
Pohl C; Renner C; Schwonzen M; Sieber M; Lorenz P; Pfreundschuh M; Diehl V
Int J Cancer; 1992 Apr; 50(6):958-67. PubMed ID: 1313400
[TBL] [Abstract][Full Text] [Related]
16. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
17. Activation of peripheral CD8+ T lymphocytes via CD28 plus CD2: evidence for IL-2 gene transcription mediated by CD28 activation.
Carabasi MH; DiSanto JP; Yang SY; Dupont B
Tissue Antigens; 1991 Jan; 37(1):26-32. PubMed ID: 1676547
[TBL] [Abstract][Full Text] [Related]
18. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
Hess AD; Bright EC
Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
[TBL] [Abstract][Full Text] [Related]
19. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
Möller SA; Reisfeld RA
Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
[TBL] [Abstract][Full Text] [Related]
20. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
